Fuso Pharmaceutical Industries,Ltd. (TYO:4538)
Japan · Delayed Price · Currency is JPY 2,109.00
+1.00 (0.05%)
Oct 23, 2026, 3:30 PM JST
TYO:4538 Financials Overview
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '13 Mar 31, 2013 | Mar '12 Mar 31, 2012 |
Revenue Revenue Growth | 62,850 | 62,307 | 60,563 | 55,407 | 48,612 | 44,358 |
Revenue Growth | 2.29% | 2.88% | 9.31% | 13.98% | 9.59% | -6.55% |
Gross Profit Gross Profit Growth | 16,115 | 15,996 | 16,533 | 13,840 | 15,316 | 12,194 |
Operating Income Operating Income Growth | 3,017 | 2,641 | 4,132 | 1,966 | 3,817 | 481 |
Net Income Net Income Growth | 2,191 | 2,011 | 2,780 | 1,377 | 4,871 | 372 |
Earnings Per Share EPS Growth | 256.62 | 235.52 | 325.43 | 159.92 | 538.01 | 41.08 |
EPS Growth | -16.02% | -27.63% | 103.50% | -70.28% | 1209.63% | -67.47% |
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '13 Mar 31, 2013 | Mar '12 Mar 31, 2012 |
Cash & Investments Cash & Investments Growth | 4,574 | 4,846 | 6,264 | 5,120 | 9,120 | 4,278 |
Total Debt Total Debt Growth | 28,161 | 31,474 | 25,919 | 22,785 | 13,217 | 13,493 |
Net Cash (Debt) Net Cash Growth | -23,587 | -26,628 | -19,655 | -17,665 | -4,097 | -9,215 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -2762.66 | -3118.54 | -2300.83 | -2051.55 | -452.52 | -1017.64 |
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '13 Mar 31, 2013 | Mar '12 Mar 31, 2012 |
Operating Cash Flow Operating Cash Flow Growth | - | -6,224 | - | - | 3,258 | 884 |
Capital Expenditures CapEx Growth | - | -1,266 | - | - | -1,928 | -1,206 |
Free Cash Flow Free Cash Flow Growth | - | -7,490 | - | - | 1,330 | -322 |
Free Cash Flow Growth | - | - | - | - | - | - |
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '13 Mar 31, 2013 | Mar '12 Mar 31, 2012 |
Gross Margin | 25.64% | 25.67% | 27.30% | 24.98% | 31.51% | 27.49% |
Operating Margin | 4.80% | 4.24% | 6.82% | 3.55% | 7.85% | 1.08% |
Pretax Margin | 4.30% | 3.91% | 6.23% | 3.19% | 12.83% | 0.02% |
Profit Margin | 3.49% | 3.23% | 4.59% | 2.48% | 10.02% | 0.84% |
FCF Margin | - | -12.02% | - | - | 2.74% | -0.73% |
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|
| Period Ending | Oct '26 Oct 25, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '13 Mar 31, 2013 | Mar '12 Mar 31, 2012 |
Dividend Per Share Dividend Per Share Growth | 90.000 | 90.000 | 82.000 | 70.000 | 60.000 | 60.000 |
Dividend Per Share Growth | 3.45% | 9.76% | 17.14% | 16.67% | 0% | 0% |
Dividend Yield | 4.27% | 3.81% | 3.39% | 3.24% | 1.45% | 2.62% |
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|
| Period Ending | Oct '26 Oct 25, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '13 Mar 31, 2013 | Mar '12 Mar 31, 2012 |
PE Ratio | 8.22 | 10.03 | 7.43 | 13.53 | 7.71 | 55.74 |
Forward PE | - | 39.53 | 39.53 | 39.53 | - | - |
P/FCF Ratio | - | - | - | - | 28.25 | - |
PS Ratio | 0.29 | 0.32 | 0.34 | 0.34 | 0.77 | 0.47 |